N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide
- CAS No.
- 1190277-80-5
- Chemical Name:
- N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide
- Synonyms
- MKI-1;MKI-1, 10 mM in DMSO;MKI-1/MASTL Kinase Inhibitor-1;N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide;N-1H-Benzimidazol-2-yl-3-(1H-pyrrol-1-yl)benzamide;Benzamide, N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl)-;N-(1H-Benzo[d]imidazol-2-yl)-3-(1H-pyrrol-1-yl)benzamide
- CBNumber:
- CB84458467
- Molecular Formula:
- C18H14N4O
- Molecular Weight:
- 302.33
- MDL Number:
- MFCD13758448
- MOL File:
- 1190277-80-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | QXB27780 | N-1H-Benzimidazol-2-yl-3-(1H-pyrrol-1-yl)benzamide | 1190277-80-5 | 25mg | $1237.25 | 2026-06-04 | Buy |
| Biosynth | QXB27780 | N-1H-Benzimidazol-2-yl-3-(1H-pyrrol-1-yl)benzamide | 1190277-80-5 | 50mg | $1721 | 2026-06-04 | Buy |
| ChemScene | CS-0139947 | MKI-1 98.13% | 1190277-80-5 | 5mg | $195 | 2026-06-04 | Buy |
| ChemScene | CS-0139947 | MKI-1 98.13% | 1190277-80-5 | 10mg | $292 | 2026-06-04 | Buy |
| ChemScene | CS-0139947 | MKI-1 98.13% | 1190277-80-5 | 25mg | $468 | 2026-06-04 | Buy |
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Chemical Properties, Uses, Production
Uses
MKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer[1].
in vivo
MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice[1].
| Animal Model: | Five-week-old female BALB/c nude mice (BT549 cells)[1]. |
| Dosage: | 50 mg/kg. |
| Administration: | Twice per week by intraperitoneal (i.p.) injection. |
| Result: | Reduced tumor growth. |
References
[1] Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10:571601. DOI:10.3389/fonc.2020.571601
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Preparation Products And Raw materials
Raw materials
Preparation Products
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Beckham Medical Technology Co., Ltd | 13816613772 | huahero21@sina.com | China | 2994 | 55 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Tianjin Kailiqi Biotechnology Co., Ltd. | 15076683720 | klq@cw-bio.com | China | 9780 | 55 |
| MQ (shanghai) Pharmaceuticals Co., Ltd. | 13761635123 | sales@linyuepharm.com | China | 5731 | 55 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Jinan Jiuli Biotechnology Co. , Ltd. | 15865264761 | 486064515@qq.com | China | 5000 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59929 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Suzhou Zhixin Biotechnology Co., Ltd. | 0512-65118909 18100677375 | sales@szzxbio.com | China | 1129 | 58 |
View Latest Price from N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide manufacturers
1190277-80-5 (N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide) Related Search:
1of2





